There Could Be Discussions on Price Reviews for Add’l Indication-Driven Sales Growth: Weber

Takeda CEO Christophe Weber Takeda Pharmaceutical CEO Christophe Weber has suggested that it might be acceptable that discussions are held on off-cycle price reviews for products generating larger-than-expected sales following indication expansions - a proposal being mooted by the government...read more